Disease · MONDO_0015517

common variable immunodeficiency

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. common variable immunodeficiency. Diseases, record MONDO_0015517. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015517

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: common variable immunodeficiency; Open Targets
Open Targets ID: MONDO_0015517; Open Targets
Other names: Acquired Hypogammaglobulinemias, Acquired hypogammaglobulinaemia, COMMON VARIABL IMMUNODEF, COMMON VARIABLE IMMUNODEFIC, CVAG, CVI - Common variable immunodeficiency, CVID, CVID - Common variable immunodeficiency, Common Variable Hypogammaglobulinemia, Common Variable Hypogammaglobulinemias, Common Variable Immune Deficiency, Common Variable Immunodeficiencies, Common variable agammaglobulinaemia, Common variable agammaglobulinemia, Common variable agammaglobulinemia (disorder), Common variable hypogammaglobulinaemia, Deficiencies, Late-Onset Immunoglobulin, Deficiency, Late-Onset Immunoglobulin, Hypogammaglobulinemia, Acquired, Hypogammaglobulinemia, Common Variable, Hypogammaglobulinemias, Acquired, Hypogammaglobulinemias, Common Variable, IMMUNODEFIC COMMON VARIABLE, Immunodeficiencies, Common Variable, Immunodeficiency, Common Variable, Immunoglobulin Deficiencies, Late-Onset, Immunoglobulin Deficiency, Late Onset, Late onset immunoglobulin deficiency, Late-Onset Immunoglobulin Deficiencies, Sporadic hypogammaglobulinemia, Variable Hypogammaglobulinemia, Common, Variable Hypogammaglobulinemias, Common, acquired Agammaglobulinemia, acquired hypogammaglobulinemia, primary antibody deficiency, primary hypogammaglobulinemia, secondary hypogammaglobulinemia; Open Targets
Disease Ontology: DOID:12177; Disease Ontology
MeSH: D017074; MeSH
NCI Thesaurus: C26725; NCI Thesaurus
Orphanet: ORPHA:1572; Orphanet
Highest stage of its drugs: Phase 3, for 1 of its 11 drugs, from ClinicalTrials.gov; Open Targets

Drugs11

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
HUMAN IMMUNOGLOBULIN G	CHEMBL1201599		Phase 3	ClinicalTrials.gov	7	7	1	Drugs and targets
ABATACEPT	CHEMBL1201823	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ALEMTUZUMAB	CHEMBL1201587	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)	CHEMBL2108981		Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
FISETIN	CHEMBL31574	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
FLUDARABINE	CHEMBL1568	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LENIOLISIB	CHEMBL3643413	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
MELPHALAN	CHEMBL852	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
USTEKINUMAB	CHEMBL1201835	Antibody	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
APILIMOD MESYLATE	CHEMBL6067997	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 11

See all 11 drugs

Targets11

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CD52	CAMPATH-1 antigen	1	CAMPATH-1 antigen inhibitor	Phase 2	https://conductscience.org/library/genes/1043	Drugs and targets
CD80	T-lymphocyte activation antigen CD80	1	T-lymphocyte activation antigen CD80 inhibitor	Phase 2	https://conductscience.org/library/genes/941	Drugs and targets
CD86	T-lymphocyte activation antigen CD86	1	T-lymphocyte activation antigen CD86 inhibitor	Phase 2	https://conductscience.org/library/genes/942	Drugs and targets
IL12A	Interleukin-12	1	Interleukin-12 inhibitor	Phase 1/2	https://conductscience.org/library/genes/3592	Drugs and targets
IL12B	Interleukin-12	1	Interleukin-12 inhibitor; Interleukin-23 inhibitor	Phase 1/2	https://conductscience.org/library/genes/3593	Drugs and targets
IL23A	Interleukin-23	1	Interleukin-23 inhibitor	Phase 1/2	https://conductscience.org/library/genes/51561	Drugs and targets
IL2RA	Interleukin-2 receptor	1	Interleukin-2 receptor agonist	Unknown	https://conductscience.org/library/genes/3559	Drugs and targets
IL2RB	Interleukin-2 receptor	1	Interleukin-2 receptor agonist	Unknown	https://conductscience.org/library/genes/3560	Drugs and targets
IL2RG	Interleukin-2 receptor	1	Interleukin-2 receptor agonist	Unknown	https://conductscience.org/library/genes/3561	Drugs and targets
PIK3CD	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	1	PI3-kinase p110-delta subunit inhibitor	Phase 2	https://conductscience.org/library/genes/5293	Drugs and targets

1 to 10 of 11

See all 11 targets

Trials8

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02199496	Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency	Phase 1/2	5	2020-08-24	Gastrointestinal Inflammation Associated With CVID, CVID Enteropathy	USTEKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT00004695	Randomized Study of Polyethylene-Glycol-Conjugated Interleukin 2 in Patients With Common Variable Immunodeficiency	Not applicable	48		Common Variable Immunodeficiency	ALDESLEUKIN	Its record names the disease	ClinicalTrials.gov
NCT04925375	Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease	Phase 2	38		Interstitial Lung Disease, Common Variable Immunodeficiency	ABATACEPT	Its record names the disease	ClinicalTrials.gov
NCT06897358	Leniolisib for Immune Dysregulation in CVID	Phase 2	27		Common Variable Immunodeficiency (CVID)	LENIOLISIB	Its record names the disease	ClinicalTrials.gov
NCT07284641	Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)	Phase 2	25		Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder, Immune Dysregulation, DiGeorge Syndrome, STAT 1 Gain of Function, STAT 3 Gain of Function, Hypomorphic RAG1 Deficiency, CD40 Ligand Deficiency, Mendelian Susceptibility to Mycobacterial Disease, GATA2 Associated Immunodeficiency, CD40 Deficiency, Hypomorphic RAG2 Deficiency, Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome, Omenn Syndrome, Chronic Granulomatous Disease	ALEMTUZUMAB, FLUDARABINE, MELPHALAN	Its record names the disease	ClinicalTrials.gov
NCT05593588	Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency	Phase 2	20		Common Variable Immunodeficiency, Interstitial Lung Disease Due to Systemic Disease	FISETIN	Its record names the disease	ClinicalTrials.gov
NCT00263237	STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency	Phase 1	10		Common Variable Immunodeficiency	APILIMOD MESYLATE	Its record names the disease	ClinicalTrials.gov
NCT02247141	A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam®	Phase 3			Primary Antibody Deficiency	HUMAN IMMUNOGLOBULIN G	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
26222441	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0015517

GET https://conductscience.org/api/diseases/v1/MONDO_0015517/drugs

API reference For AI assistants